Fig. 2

The DNMT3A mutation results in high expression of NAMPT and aberrant NAM-NAD metabolism. A NAMPT expression levels in patient samples with DNMT3A wild-type, DNMT3A-R882H mutation, DNMT3A-R882C mutation and other mutation sites in AML (n = 200) in the TCGA database. B The volcano map showed the higher expression of NAMPT in U937^MUT compared with the U937^WT and U937^VEC. C Q-RT-PCR showed the mRNA expression level of NAMPT in U937, U937^VEC, U937^WT and U937^MUT. D Immunoblotting showed the protein level of NAMPT in U937, U937^VEC, U937^WT and U937^MUT. E The content of original intracellular NAD + /NADH and the NAD + /NADH converted from NAM with NAMPT in the U937, U937^VEC, U937^WT and U937^MUT. F GO enrichment analysis of the differential genes in U937^MUT vs. U937^WT. G GO enrichment analysis of the differential genes in leukemic cells in patient samples with the DNMT3A R882 mutation vs. the DNMT3A wild-type. H The Venn diagram showed 40 common abnormal metabolic pathways in GSE27187, GSE90931 and Dnmt3a^R878H/WT mouse model. The mean ± SD of minimum n = 3 independent experiments is displayed, representative images shown *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 (Student’s T-test)